- [PRESSWIRE] 爱尔兰都柏林 —— 2026年3月11日 —— 总部位于都柏林的全球美学公司 EMA Aesthetics（www.emaaesthetics.com）宣布对 MonoTx Global Holdings, Inc.（MonoTx） 进行战略投资。此次投资将加强双方在下一代再生医学美容领域的合作，并为长期创新发展奠定更坚实的基础。
- 【PRESSWIRE】愛爾蘭都柏林 – 2026年3月11日 – 全球美學公司 EMA Aesthetics（www.emaaesthetics.com）欣然宣佈對 MonoTx Global Holdings, Inc.（「MonoTx」）進行策略性投資，進一步加強雙方於次世代再生美學領域的合作，並為長期創新奠定穩固基礎。
- [PRESSWIRE] Dublin, Ireland – 11th March, 2026 – EMA Aesthetics (www.emaaesthetics.com), a global aesthetics company headquartered in Dublin, is pleased to announce a strategic investment in MonoTx Global Holdings, Inc. (“MonoTx”), strengthening the companies’ collaboration in next-generation regenerative aesthetics and expanding the foundation for long-term innovation.
- [PRESSWIRE] FRANCE – 18 February, 2026 — Théa, an independent pharmaceutical group dedicated exclusively to eye care, announces the development of a structured roadmap to reduce its greenhouse gas emissions, in alignment with international climate objectives and the global ambition of carbon neutrality by 2045.
- [PRESSWIRE] Dar es Salaam, Tanzania – 10th February, 2026 – 10 February, 2026 — Tanzania has made significant strides in reducing the risk of epilepsy-related deaths, with the national mortality rate dropping from six percent to four percent in recent years.
- [PRESSWIRE] London, UK – 9 February, 2026 — Optimed Ltd, today announced a strategic partnership with I-Clarity to integrate Optimed’s innovative ReferAI solution into the I-Clarity’s optometry practice management software. ReferAI vastly speeds up the referral workflow and enhances 2-way communication with ophthalmology.
- [PRESSWIRE] DODOMA, Tanzania — 24th January, 2026 — Tanzania has begun rolling out a nationwide universal health insurance programme, joining a growing number of African countries seeking to expand access to healthcare through state-backed systems.
- [PRESSWIRE] Grenoble, France — January 21, 2026 — Diabeloop, a pioneer in therapeutic artificial intelligence, announces that its DBLG2 AID has become the first solution cleared by both the U.S. Food and Drug Administration (FDA) and the CE Mark where meal announcements are no longer mandatory. Although not announcing meals might lead to a lower glycemic control, this offers choice to the patients in managing diabetes in their everyday life. This marks a major step forward in the evolution of automated insulin delivery and a meaningful milestone toward a fully closed-loop system.
- Companies anticipate product readiness by end of 2026 and launch in the US in 2027. Integration will give people with diabetes more choice in how they manage their diabetes care with twiist.
- Diabeloop receives FDA 510(k) clearance for DBLG2, an Automated Insulin Delivery algorithm in an App: a strategic turning point. The company confirms its status as a global reference partner for automated insulin delivery, with the validation of its DBLG2 algorithm and its predetermined Change Control Plan (PCCP) by the FDA.
- [PRESSWIRE] STOCKHOLM – Dec. 18, 2025 — Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held in person in Stockholm, Sweden, on 18 February 2026, starting at 13:00 CET. A live webcast will also be available for remote participants.
- [PRESSWIRE] Geneva – October 20, 2025 – SGS, the world’s leading testing, inspection and certification company, has unveiled ‘SGS DIGITAL TRUST: Across technologies, services and organizations’ a new global framework that unites its digital trust services into one structured and consistent approach.
- [PRESSWIRE] CAMBRIDGE, Mass., Sept. 16, 2025 — Flagship Pioneering, a scientific innovation engine for platforms and products, and Vesalius Therapeutics, a company pioneering a revolutionary platform to redefine common diseases for breakthroughs in treatments, targets and clinical trials, today announced the appointment of Yasir Al-Wakeel, BM BCh (Doctor of Medicine and Surgery), as CEO-Partner of Flagship and CEO of Vesalius. He succeeds John Mendlein, Executive Partner at Flagship Pioneering, who has served as interim CEO and will continue in his role as Executive Chairman.
- [PRESSWIRE] Schenectady, NY – 22 August, 2025 — Utech Products Inc., the parent company of EndoSoft, LLC., which is a leader in advanced AI-driven medical software, announced today that the European Patent office (EPO) has issued European Patent No. EP 3 930 610 B1, titled “AI Systems for Detecting and Sizing Lesions.”
- [PRESSWIRE] Melbourne, Australia – July 10, 2025 — As mental health services around the world grapple with rising demand and limited access, a new 2025 study points to a powerful digital solution for people living with posttraumatic stress disorder (PTSD)- especially those unable to access regular therapy.
- Diabeloop announces Commercial Availability of DBLG1 with Dana-i Insulin Pump in Germany.
- [PRESSWIRE] ANDERNACH, Germany and MONTREAL – June 25, 2025 — LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality and cost-competitive large-scale manufacturing capacities.
- [PRESSWIRE] London, UK – 27 May, 2025 — With only a few weeks to go, pre-registration is building fast for EBME Expo 2025, the UK’s leading healthcare technology exhibition and conference series.
- Strategic collaboration addresses critical gaps in care for families affected by Duchenne muscular dystrophy and chronic conditions…
- [PRESSWIRE] US – 05.05.25 — Join the L2 Bio® Stem Cell Revolution. L2 Bio® currently has over 50 Stem Cell Centers across the USA and is thrilled to announce the official launch of the L2 300 Expansion Initiative which has secured the funding necessary to open 300 additional Stem Cell Centers of Excellence over the next 12 months.
- [PRESSWIRE] NY, US – 25.04.25 — Dr. Ken Moadel, New York’s most trusted name in eye care for over 30 years, is now available in 4 NYC boroughs.
- Unique Service to Link Consumers with Physicians for Written Opinions on Potential Negligence
- Veterinary professionals take an oath to benefit society first, then animals. But are they prepared to benefit an ever-diverse society of animal owners?
- [PRESSWIRE] France – 12.12.24 — Clermont-Ferrand, France, December 12th, 2024 – Sepul Bio, an innovative business unit of Laboratoires Théa (“Théa”)dedicated to the advancement of RNA therapies for inherited retinal diseases, has today announced the first clinical participant has been dosed in LUNA clinical study, a Phase 2b clinical study for ultevursen, in individuals with retinitis pigmentosa (RP) or non-syndromic RP due to variants in exon 13 of the Usher Syndrome Type 2a gene.
- [PRESSWIRE] London, UK – 07.11.24 — Thirty years after treatment for chronic asthma and psoriasis Stephanie remains symptom free.
- New Nikon BioImaging Labs opening, providing solutions to your assay development, microscope-based imaging and image analysis needs…
- A groundbreaking real-world study involving over 9,000 adults with type 1 diabetes has uncovered important differences between males and females in insulin requirements…
- [PRESSWIRE] AMSTERDAM, THE NETHERLANDS – 04 July, 2024 — Nikon Europe B.V. (Nikon) will launch the ECLIPSE Ti2-I Motorized Inverted Microscope for ICSI*3/IMSI*4, specialized for use in micro-insemination, from July 5. By allowing the microscope settings to be automatically controlled via simple buttons and a touch screen close to your hands – we’ve improved efficiency by reducing the steps required for operation by approximately 75%. An alert function and bright, clear field of view support accurate operation.
- [PRESSWIRE] Nottingham, UK – June 4th, 2024 — 4D Medicine Limited has appointed Dr Tom Buckland as its new Chairman and Non-executive Director.
- [PRESSWIRE] IRELAND – 14 May, 2024 — A group of the world’s leading experts in the treatment of stroke are calling on the EU to make sweeping changes to regulations governing the development of medical devices, adding that the current rules are inhibiting innovation and preventing patients from accessing life-saving care.